ALT
NASDAQ · Biotechnology
Altimmune Inc
$3.31
+0.07 (+2.16%)
Open$3.30
Previous Close$3.24
Day High$3.39
Day Low$3.24
52W High$7.73
52W Low$2.90
Volume—
Avg Volume3.46M
Market Cap434.43M
P/E Ratio—
EPS$-1.00
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+218.7% upside
Current
$3.31
$3.31
Target
$10.55
$10.55
$6.68
$10.55 avg
$11.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 65.0K | 232.2K | 252.74M |
| Net Income | -130,056,978 | -932,514,656 | 22.15M |
| Profit Margin | -214,861.0% | -451,530.3% | 8.8% |
| EBITDA | -139,617,121 | -1,065,342,972 | 31.01M |
| Free Cash Flow | — | — | 16.83M |
| Rev Growth | — | -83.5% | +1.7% |
| Debt/Equity | 0.15 | — | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |